Billionaire entrepreneur Elon Musk shared on Monday, January 29, that Neuralink, his brain-chip startup, successfully implanted its first human patient on Sunday, January 28, and that the individual is recovering well.
Last year, the US Food and Drug Administration (FDA) granted Neuralink clearance to initiate its first trial for testing the brain implant on humans. Musk stated that the initial results indicate promising detection of neuron spikes.
Neuron spikes refer to the activity of neurons, cells that use electrical and chemical signals to transmit information within the brain and to the body.
The trial, known as the Prime study, is designed to assess the safety and functionality of Neuralink's wireless brain-computer interface, enabling individuals with quadriplegia to control devices using their thoughts.
The successful implant marks a significant milestone for Neuralink, valued at up to $5 billion according to private stock trades. The company received FDA clearance for its human trial in 2023, and the study involves the use of a surgical robot to place ultra-fine threads that transmit signals into participants' brains.
No comments:
Post a Comment